KIM\_WT1\_TARGETS\_12HR\_UP, KIM\_WT1\_TARGETS\_12HR\_UP HOOI\_ST7\_TARGETS\_DN, HOOI\_ST7\_TARGETS\_DN WIERENGA\_STAT5A\_TARGETS\_GROUP2, WIERENGA\_STAT5A\_TARGETS\_GROUP2 MEBARKI\_HCC\_PROGENITOR\_WNT\_UP\_CTNNB1\_DEPENDENT, MEBARKI\_HCC\_PROGENITOR\_WNT\_UP\_CTNNB1\_DEPENDENT LI\_WILMS\_TUMOR\_VS\_FETAL\_KIDNEY\_2\_DN, LI\_WILMS\_TUMOR\_VS\_FETAL\_KIDNEY\_2\_DN ISSAEVA\_MLL2\_TARGETS, ISSAEVA\_MLL2\_TARGETS HUANG\_FOXA2\_TARGETS\_UP, HUANG\_FOXA2\_TARGETS\_UP COWLING\_MYCN\_TARGETS, COWLING\_MYCN\_TARGETS YAO\_TEMPORAL\_RESPONSE\_TO\_PROGESTERONE\_CLUSTER\_6, YAO\_TEMPORAL\_RESPONSE\_TO\_PROGESTERONE\_CLUSTER\_6 BOYLAN\_MULTIPLE\_MYELOMA\_C\_CLUSTER\_DN, BOYLAN\_MULTIPLE\_MYELOMA\_C\_CLUSTER\_DN MANNE\_COVID19\_ICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_ICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP GAVIN\_FOXP3\_TARGETS\_CLUSTER\_P7, GAVIN\_FOXP3\_TARGETS\_CLUSTER\_P7 MANNE\_COVID19\_NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP BOYAULT\_LIVER\_CANCER\_SUBCLASS\_G5\_DN, BOYAULT\_LIVER\_CANCER\_SUBCLASS\_G5\_DN SEITZ\_NEOPLASTIC\_TRANSFORMATION\_BY\_8P\_DELETION\_UP, SEITZ\_NEOPLASTIC\_TRANSFORMATION\_BY\_8P\_DELETION\_UP T\_HSC\_S1PR3\_OE\_UP, XIE\_ST\_HSC\_S1PR3\_OE\_UP BEGUM\_TARGETS\_OF\_PAX3\_FOXO1\_FUSION\_DN, BEGUM\_TARGETS\_OF\_PAX3\_FOXO1\_FUSION\_DN KIM\_LRRC3B\_TARGETS, KIM\_LRRC3B\_TARGETS DAUER\_STAT3\_TARGETS\_DN, DAUER\_STAT3\_TARGETS\_DN HAHTOLA\_CTCL\_PATHOGENESIS, HAHTOLA\_CTCL\_PATHOGENESIS TURASHVILI\_BREAST\_LOBULAR\_CARCINOMA\_VS\_DUCTAL\_NORMAL\_UP, TURASHVILI\_BREAST\_LOBULAR\_CARCINOMA\_VS\_DUCTAL\_NORMAL\_UP BENNETT\_SYSTEMIC\_LUPUS\_ERYTHEMATOSUS, BENNETT\_SYSTEMIC\_LUPUS\_ERYTHEMATOSUS BOWIE RESPONSE TO TAMOXIFEN, BOWIE RESPONSE TO TAMOXIFEN ZHAN\_MULTIPLE\_MYELOMA\_LB\_DN, ZHAN\_MULTIPLE\_MYELOMA\_LB\_DN SALVADOR\_MARTIN\_PEDIATRIC\_TBD\_ANTI\_TNF\_THERAPY\_NONRESPONDER\_PRE\_TREATMENT\_UP, SALVADOR\_MARTIN\_PEDIATRIC\_TBD\_ANTI\_TNF\_THERAPY\_NONRESPONDER\_ MOROSETTI\_FACIOSCAPULOHUMERAL\_MUSCULAR\_DISTROPHY\_UP, MOROSETTI\_FACIOSCAPULOHUMERAL\_MUSCULAR\_DISTROPHY\_UP GAUTSCHI\_SRC\_SIGNALING, GAUTSCHI\_SRC\_SIGNALING GARGALOVIC\_RESPONSE\_TO\_OXIDIZED\_PHOSPHOLIPIDS\_GREY\_DN, GARGALOVIC\_RESPONSE\_TO\_OXIDIZED\_PHOSPHOLIPIDS\_GREY\_DN HAHTOLA\_SEZARY\_SYNDROM\_DN, HAHTOLA\_SEZARY\_SYNDROM\_DN VALK AML CLUSTER 11, VALK AML CLUSTER 11 FRIDMAN\_IMMORTALIZATION\_DN, FRIDMAN\_IMMORTALIZATION\_DN GRANDVAUX\_IFN\_RESPONSE\_NOT\_VIA\_IRF3, GRANDVAUX\_IFN\_RESPONSE\_NOT\_VIA\_IRF3 FONTAINE THYROID TUMOR\_UNCERTAIN\_MALIGNANCY\_DN, FONTAINE THYROID\_TUMOR\_UNCERTAIN\_MALIGNANCY\_DN SASSON\_RESPONSE\_TO\_FORSKOLIN\_DN, SASSON\_RESPONSE\_TO\_FORSKOLIN\_DN MATTHEWS\_AP1\_TARGETS, MATTHEWS\_AP1\_TARGETS BORLAK\_LIVER\_CANCER\_EGF\_UP, BORLAK\_LIVER\_CANCER\_EGF\_UP

DORN\_ADENOVIRUS\_INFECTION\_12HR\_UP, DORN\_ADENOVIRUS\_INFECTION\_12HR\_UP

MEBARKI\_HCC\_PROGENITOR\_WNT\_UP, MEBARKI\_HCC\_PROGENITOR\_WNT\_UP

KRIEG\_KDM3A\_TARGETS\_NOT\_HYPOXIA, KRIEG\_KDM3A\_TARGETS\_NOT\_HYPOXIA

PLASARI\_TGFB1\_TARGETS\_1HR\_UP, PLASARI\_TGFB1\_TARGETS\_1HR\_UP

DORSEY\_GAB2\_TARGETS, DORSEY\_GAB2\_TARGETS

RYAN\_MANTLE\_CELL\_LYMPHOMA\_NOTCH\_DIRECT\_UP, RYAN\_MANTLE\_CELL\_LYMPHOMA\_NOTCH\_DIRECT\_UP

JECHLINGER\_EPITHELIAL\_TO\_MESENCHYMAL\_TRANSITION\_UP, JECHLINGER\_EPITHELIAL\_TO\_MESENCHYMAL\_TRANSITION\_UP

MEISSNER\_NPC\_HCP\_WITH\_H3K4ME3\_AND\_H3K27ME3, MEISSNER\_NPC\_HCP\_WITH\_H3K4ME3\_AND\_H3K27ME3